Erythropoietin improves memory function with reducing endothelial dysfunction and amyloid‐beta burden in Alzheimer’s disease models
The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
J. Neurochem. (2012) 120, 115–124. Neurovascular degeneration contributes to the pathogenesis of Alzheimer’s disease (AD). Because erythropoietin (EPO) promotes endothelial regeneration, we investigated the therapeutic effects of EPO in animal models of AD. In aged Tg2576 mice, EPO receptors (EPORs) were expressed in the cortex and hippocampus. Tg2576 mice were treated with daily injection of EPO (5000 IU/kg/day) for 5 days. At 14 days, EPO improved contextual memory as measured by fear‐conditioning test. EPO enhanced endothelial proliferation and the level of synaptophysin expression in the brain. EPO also increased capillary density, and decreased the level of the receptor for advanced glycation endproducts (RAGE) in the brain, while decreasing in the amount of amyloid plaque and amyloid‐β (Aβ). In cultured human endothelial cells, EPO enhanced angiogenesis and suppressed the expression of the RAGE. These results show that EPO improves memory and ameliorates endothelial degeneration induced by Aβ in AD models. This pre‐clinical evidence suggests that EPO may be useful for the treatment of AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Querfurth, H. W., & LaFerla, F. M. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0909142 · Cited by 4,569
RAGE and amyloid-β peptide neurotoxicity in Alzheimer's disease
Yan, S. D., Chen, X., Fu, J., Chen, M., Zhu, H., Roher, A., Slattery, T., Zhao, L., Nagashima, M., Morser, J., et al. (1996) · Nature · doi:10.1038/382685a0 · Cited by 2,012 · cited 5×
“Clearance of Ab in AD brain partly depends on the action of endothelial transporters, such as RAGE and low density lipoprotein receptor-related protein 1(Shibata et al. 2000; Yan et al. 1996).”
BackgroundInfluentialRAGE mediates amyloid-β peptide transport across the blood-brain barrier and accumulation in brain
Deane, R., Du Yan, S., Submamaryan, R. K., LaRue, B., Jovanovic, S., Hogg, E., Welch, D., Manness, L., Lin, C., Yu, J., et al. (2003) · Nature Medicine · doi:10.1038/nm890 · Cited by 1,611
Shibata, M., Yamada, S., Kumar, S. R., Calero, M., Bading, J., Frangione, B., Holtzman, D. M., Miller, C. A., Strickland, D. K., Ghiso, J., et al. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10498 · Cited by 1,413 · cited 1×
“Clearance of Ab in AD brain partly depends on the action of endothelial transporters, such as RAGE and low density lipoprotein receptor-related protein 1(Shibata et al. 2000; Yan et al. 1996).”
BackgroundIncreased hippocampal neurogenesis in Alzheimer's disease
Jin, K., Peel, A. L., Mao, X. O., Xie, L., Cottrell, B. A., Henshall, D. C., & Greenberg, D. A. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2634794100 · Cited by 971 · cited 1×
“However, increased neurogenesis has been described in AD patients and young amyloid precursor protein transgenic mice (Jin et al. 2004; Lopez-Toledano et al. 2010).”
BackgroundEvolution of the neuropathology of Alzheimer's disease
Braak, H., & Braak, E. (1996) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1996.tb05866.x · Cited by 710 · cited 2×
“Alzheimer’s disease is the most common cause of senile dementia and is characterized by a progressive decline in cognitive function, neuronal degeneration, and the accumulation of extracellular amyloid (senile plaques) and intracellular inclusions (neurofibrillary tangles) (Braak and Braak 1996; Querfurth and LaFerla…”
BackgroundEarly-onset behavioral and synaptic deficits in a mouse model of Alzheimer's disease
Jacobsen, J. S., Wu, C.-C., Redwine, J. M., Comery, T. A., Arias, R., Bowlby, M., Martone, R., Morrison, J. H., Pangalos, M. N., Reinhart, P. H., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0600948103 · Cited by 701
Recombinant Human Erythropoietin in the Treatment of Acute Ischemic Stroke
Ehrenreich, H., Weissenborn, K., Prange, H., Schneider, D., Weimar, C., Wartenberg, K., Schellinger, P. D., Bohn, M., Becker, H., Wegrzyn, M., et al. (2009) · Stroke · doi:10.1161/strokeaha.109.564872 · Cited by 605
Dong, H., Goico, B., Martin, M., Csernansky, C. A., Bertchume, A., & Csernansky, J. G. (2004) · Neuroscience · doi:10.1016/j.neuroscience.2004.05.040 · Cited by 342 · cited 1×
“Impaired neurogenesis is likely to contribute to memory loss in AD (Dong et al. 2004).”
BackgroundFang, F., Lue, L.-F., Yan, S., Xu, H., Luddy, J. S., Chen, D., Walker, D. G., Stern, D. M., Yan, S., Schmidt, A. M., et al. (2010) · The FASEB Journal · doi:10.1096/fj.09-139634 · Cited by 335 · cited 2×
“2009), and microglial RAGE contributes to neuroinflammation (Fang et al. 2010).”
BackgroundRAGE-mediated signaling contributes to intraneuronal transport of amyloid-β and neuronal dysfunction
Takuma, K., Fang, F., Zhang, W., Yan, S., Fukuzaki, E., Du, H., Sosunov, A., McKhann, G., Funatsu, Y., Nakamichi, N., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0905686106 · Cited by 290 · cited 2×
“Neuronal RAGE participates in the intraneuronal transport of Ab, synaptic dysfunction, and expression of b-site of amyloid precursor protein cleaving enzyme (Cho et al. 2009; Origlia et al. 2008; Takuma et al. 2009), and microglial RAGE contributes to neuroinflammation (Fang et al. 2010).”
BackgroundReduced circulating angiogenic cells in Alzheimer disease
Lee, S.-T., Chu, K., Jung, K.-H., Park, H.-K., Kim, D.-H., Bahn, J.-J., Kim, J.-H., Oh, M.-J., Lee, S. K., Kim, M., et al. (2009) · Neurology · doi:10.1212/wnl.0b013e3181a711f4 · Cited by 61 · cited 4×
“(2012) 120, 115–124 115 addition, reduced cerebral capillary density and a decreased ability of the endothelium to regenerate are found in and may contribute to AD (Lee et al. 2009b; Weller et al. 2008).”
BackgroundMethodInfluentialSelf-citation
Cited by
Shedding new light on neurodegenerative diseases through the mammalian target of rapamycin
Chong, Z. Z., Shang, Y. C., Wang, S., & Maiese, K. (2012) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2012.08.001 · Cited by 119
“exposure (Chong et al., 2005c; Lee et al., 2012; Liu et al., 2010b; Shang et al., 2012; Zeng et al., 2011) can be the result of oxidant stress.”
BackgroundOxidant Stress and Signal Transduction in the Nervous System with the PI 3-K, Akt, and mTOR Cascade
Maiese, K., Chong, Z. Z., Wang, S., & Shang, Y. C. (2012) · International Journal of Molecular Sciences · doi:10.3390/ijms131113830 · Cited by 109
Thomas, R., Zuchowska, P., Morris, A. W. J., Marottoli, F. M., Sunny, S., Deaton, R., Gann, P. H., & Tai, L. M. (2016) · Acta Neuropathologica Communications · doi:10.1186/s40478-016-0387-3 · Cited by 72
“Our data with EGF and published data with other factors that increase total vessel coverage support an alternative approach [3, 26, 27, 32], which is to stabilize brain endothelial cells and maintain or increase”
Tikhonova, M. A., Amstislavskaya, T. G., Belichenko, V. M., Fedoseeva, L. A., Kovalenko, S. P., Pisareva, E. E., Avdeeva, A. S., Kolosova, N. G., Belyaev, N. D., & Aftanas, L. I. (2018) · BMC Neuroscience · doi:10.1186/s12868-018-0412-5 · Cited by 30
“Abbreviations Aβ: amyloid-beta; ACE: angiotensin-converting enzyme; Ace: gene of ACE; ACE2: angiotensin-converting enzyme 2; Ace2: gene of ACE2; AD: Alzheimer’s disease; Aktb: gene of β-actin; ALT: alanine aminotransferase; APP: amyloid precursor protein; App: gene of APP; ARE: antioxidant response element; AST: aspar…”
Metadata
- Authors
- Lee, S., Chu, K., Park, J., Jung, K., Jeon, D., Lim, J., Lee, S. K., Kim, M., & Roh, J.
- Venue
- Journal of Neurochemistry
- Publisher
- Wiley
- Published
- 2011-11-11
- Volume
- 120
- Issue
- 1
- Pages
- 115-124
- ISSN
- 0022-3042 (ISSN-L)
- 1471-4159
- OpenAlex
- W1572873489
- Cited by
- 84
- References
- 12
- FWCI
- 3.85
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.